CY1114165T1 - Παραγωγο 7-πιπεριδινοαλκυλ-3,4-διυδροκινολονης - Google Patents
Παραγωγο 7-πιπεριδινοαλκυλ-3,4-διυδροκινολονηςInfo
- Publication number
- CY1114165T1 CY1114165T1 CY20131100633T CY131100633T CY1114165T1 CY 1114165 T1 CY1114165 T1 CY 1114165T1 CY 20131100633 T CY20131100633 T CY 20131100633T CY 131100633 T CY131100633 T CY 131100633T CY 1114165 T1 CY1114165 T1 CY 1114165T1
- Authority
- CY
- Cyprus
- Prior art keywords
- disorder
- hydrate
- eating
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Για την παροχή μιας νέας ένωσης, ενός φαρμακευτικώς αποδεκτού άλατος ή ενός ένυδρου άλατος αυτής χρήσιμης για την πρόληψη ή θεραπεία κατάθλιψης, αγχωδών διαταραχών (όπως γενικευμένη αγχώδης διαταραχή, διαταραχή μετατραυματικού στρες, διαταραχή πανικού, ψυχαναγκαστική-καταναγκαστική διαταραχή ή κοινωνική αγχώδης διαταραχή), διαταραχής ελλειμματικής προσοχής, μανίας, μανιοκαταθλιπτικής νόσου, σχιζοφρένειας, διαταραχών της διάθεσης, στρες, διαταραχών του ύπνου, κρίσεων, εξασθένησης της μνήμης, γνωστικής εξασθένησης, άνοιας, αμνησίας, παραληρήματος, παχυσαρκίας, διαταραχής στην πρόσληψη τροφής, διαταραχής της όρεξης, υπερφαγίας, βουλιμίας, φοβίας στο φαγητό, διαβήτη, καρδιαγγειακών νόσων, υπέρτασης, δυσλιπιδαιμίας, εμφράγματος του μυοκαρδίου, κινητικής διαταραχής (όπως νόσος του Πάρκινσον, επιληψία, σπασμός ή τρόμος), φαρμακευτικής κατάχρησης, εθισμού σε ουσίες ή σεξουαλικής δυσλειτουργίας, με βάση μια ανταγωνιστική του υποδοχέα ορμόνης συγκέντρωσης μελανίνης (ΜCH) δράση. ΛΥΣΗ Μια ένωση, ένα φαρμακευτικώς αποδεκτό άλας ή ένα ένυδρο άλας αυτής που παριστάνεται με τον τύπο (I).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008257072 | 2008-10-02 | ||
| EP09817928.6A EP2344471B1 (en) | 2008-10-02 | 2009-09-30 | 7-piperidinoalkyl-3,4-dihydroquinolone derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114165T1 true CY1114165T1 (el) | 2016-08-31 |
Family
ID=42073652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131100633T CY1114165T1 (el) | 2008-10-02 | 2013-07-25 | Παραγωγο 7-πιπεριδινοαλκυλ-3,4-διυδροκινολονης |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8461182B2 (el) |
| EP (1) | EP2344471B1 (el) |
| JP (1) | JP5541279B2 (el) |
| KR (1) | KR20110067026A (el) |
| CN (1) | CN102239159B (el) |
| AR (1) | AR073727A1 (el) |
| AU (1) | AU2009300607C1 (el) |
| BR (1) | BRPI0925343A2 (el) |
| CA (1) | CA2739513A1 (el) |
| CL (1) | CL2011000734A1 (el) |
| CO (1) | CO6321164A2 (el) |
| CY (1) | CY1114165T1 (el) |
| DK (1) | DK2344471T3 (el) |
| ES (1) | ES2424393T3 (el) |
| HR (1) | HRP20130728T1 (el) |
| IL (1) | IL212070A (el) |
| MX (1) | MX2011003500A (el) |
| MY (1) | MY154337A (el) |
| NZ (1) | NZ592008A (el) |
| PE (1) | PE20110410A1 (el) |
| PL (1) | PL2344471T3 (el) |
| PT (1) | PT2344471E (el) |
| RS (1) | RS52964B (el) |
| RU (1) | RU2498981C2 (el) |
| SI (1) | SI2344471T1 (el) |
| UA (1) | UA105187C2 (el) |
| WO (1) | WO2010038901A1 (el) |
| ZA (1) | ZA201102315B (el) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011219467A (ja) * | 2010-03-26 | 2011-11-04 | Taisho Pharmaceutical Co Ltd | ７−ピペリジノアルキル−３，４−ジヒドロキノロン誘導体を含有する医薬 |
| US9512111B2 (en) | 2010-11-08 | 2016-12-06 | Lycera Corporation | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease |
| EP2846804B1 (en) | 2012-05-08 | 2017-11-29 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| AU2013259624B2 (en) | 2012-05-08 | 2017-10-19 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| ES2998534T3 (en) | 2013-03-12 | 2025-02-20 | Bio Pharm Solutions Co Ltd | Phenyl carbamate compounds for use in preventing or treating pediatric epilesy |
| WO2015095792A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease |
| WO2015095788A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| US9809561B2 (en) | 2013-12-20 | 2017-11-07 | Merck Sharp & Dohme Corp. | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
| WO2015131035A1 (en) | 2014-02-27 | 2015-09-03 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods |
| EP3209641A4 (en) | 2014-05-05 | 2018-06-06 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease |
| EP3140291A4 (en) | 2014-05-05 | 2018-01-10 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| EP3256450B1 (en) | 2015-02-11 | 2020-12-02 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof |
| JP2018515491A (ja) | 2015-05-05 | 2018-06-14 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物 |
| KR20180025894A (ko) | 2015-06-11 | 2018-03-09 | 라이세라 코퍼레이션 | Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료 |
| JP2018531957A (ja) | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ＲＯＲγＴ阻害薬としての置換二環式ピラゾール化合物及びその使用 |
| RU2018117503A (ru) | 2015-10-27 | 2019-11-28 | Мерк Шарп И Доум Корп. | ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ |
| AU2016344118A1 (en) | 2015-10-27 | 2018-05-10 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
| SG11201806416XA (en) * | 2016-02-12 | 2018-08-30 | Astellas Pharma Inc | Tetrahydroisoquinoline derivatives |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2167874C2 (ru) * | 1995-09-15 | 2001-05-27 | Санофи-Синтелябо | Производные хинолин-2(1н)-она, способы их получения, лекарственное средство и фармацевтическая композиция на их основе |
| CN1582281A (zh) | 2001-10-01 | 2005-02-16 | 大正制药株式会社 | Mch受体拮抗剂 |
| CN1585751A (zh) * | 2001-10-25 | 2005-02-23 | 武田药品工业株式会社 | 喹啉化合物 |
| US20050197350A1 (en) | 2003-03-31 | 2005-09-08 | Taisho Pharmaceutical Co., Ltd. | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| EP1611109A4 (en) | 2003-03-31 | 2009-06-24 | Taisho Pharmaceutical Co Ltd | NOVEL QUINAZOLINE DERIVATIVES AND THEIR THERAPEUTIC USE |
| US20050209274A1 (en) * | 2004-02-26 | 2005-09-22 | Lynch John K | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| ZA200607639B (en) | 2004-03-30 | 2008-05-28 | Taisho Pharmaceutical Co Ltd | Pyrimidine derivatives and methods of treatment related to the use thereof |
| WO2006035967A1 (en) | 2004-09-30 | 2006-04-06 | Taisho Pharmaceutical Co., Ltd. | Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor |
| RU2009117182A (ru) * | 2006-10-06 | 2010-11-20 | Тайсо Фармасьютикал Ко., Лтд. (Jp) | Производное 1-нафтилалкилпиперидина |
-
2009
- 2009-09-30 AU AU2009300607A patent/AU2009300607C1/en not_active Ceased
- 2009-09-30 KR KR1020117007343A patent/KR20110067026A/ko not_active Ceased
- 2009-09-30 MY MYPI2011001430A patent/MY154337A/en unknown
- 2009-09-30 CA CA2739513A patent/CA2739513A1/en not_active Abandoned
- 2009-09-30 HR HRP20130728AT patent/HRP20130728T1/hr unknown
- 2009-09-30 PE PE2011000810A patent/PE20110410A1/es not_active Application Discontinuation
- 2009-09-30 NZ NZ592008A patent/NZ592008A/en not_active IP Right Cessation
- 2009-09-30 CN CN200980149091.2A patent/CN102239159B/zh not_active Expired - Fee Related
- 2009-09-30 PL PL09817928T patent/PL2344471T3/pl unknown
- 2009-09-30 SI SI200930738T patent/SI2344471T1/sl unknown
- 2009-09-30 EP EP09817928.6A patent/EP2344471B1/en active Active
- 2009-09-30 RU RU2011117161/04A patent/RU2498981C2/ru not_active IP Right Cessation
- 2009-09-30 US US13/122,281 patent/US8461182B2/en not_active Expired - Fee Related
- 2009-09-30 UA UAA201105428A patent/UA105187C2/uk unknown
- 2009-09-30 PT PT98179286T patent/PT2344471E/pt unknown
- 2009-09-30 DK DK09817928.6T patent/DK2344471T3/da active
- 2009-09-30 MX MX2011003500A patent/MX2011003500A/es active IP Right Grant
- 2009-09-30 JP JP2011513768A patent/JP5541279B2/ja not_active Expired - Fee Related
- 2009-09-30 WO PCT/JP2009/067441 patent/WO2010038901A1/en not_active Ceased
- 2009-09-30 ES ES09817928T patent/ES2424393T3/es active Active
- 2009-09-30 RS RS20130370A patent/RS52964B/sr unknown
- 2009-09-30 BR BRPI0925343-2A patent/BRPI0925343A2/pt not_active IP Right Cessation
- 2009-10-01 AR ARP090103798A patent/AR073727A1/es unknown
-
2011
- 2011-03-29 ZA ZA2011/02315A patent/ZA201102315B/en unknown
- 2011-03-30 CO CO11038711A patent/CO6321164A2/es active IP Right Grant
- 2011-03-31 IL IL212070A patent/IL212070A/en not_active IP Right Cessation
- 2011-04-01 CL CL2011000734A patent/CL2011000734A1/es unknown
-
2013
- 2013-07-25 CY CY20131100633T patent/CY1114165T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1114165T1 (el) | Παραγωγο 7-πιπεριδινοαλκυλ-3,4-διυδροκινολονης | |
| BRPI0408910A (pt) | composto, composição farmacêutica e métodos para a profilaxia ou o tratamento de doenças ou condições e para a produção de uma composição farmacêutica | |
| WO2005095357A3 (en) | Pyrimidine derivatives and methods of treatment related to the use thereof | |
| NO20075624L (no) | Nye histamin H3-reseptorligander og deres terapeutiske anvendelser | |
| EA201070903A1 (ru) | Замещенные спироциклические производные пиперидина как лиганды гистамин-3(h) рецептора | |
| JP2009536161A5 (el) | ||
| PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
| ATE539063T1 (de) | Regioselektive, kupferkatalysierte synthese von benzimidazolen und azabenzimidazolen | |
| EA201070091A1 (ru) | Производные пиперидина, пригодные в качестве антагонистов рецептора орексина | |
| WO2007146758A3 (en) | Novel mch receptor antagonists | |
| CL2013003485A1 (es) | Compuestos derivados de benzamida sustituida como moduladores de receptores asociados con las aminas traza (taar1); composición farmacéutica; procedimiento de preparación; y uso en el tratamiento de depresión, psicosis, enfermedad de parkinson, ansiedad, trastorno de hiperactividad (adhd) y diabetes. | |
| BRPI0721088B8 (pt) | processo para a preparação de derivados de piperazinil e diazepanil benzamida | |
| CY1110531T1 (el) | 6-υποκατεστημενες-2,3,4,5-τετραϋδρο-1η-βενζο[d]αζεπινες ως αγωνιστες του υποδοχεα 5-ht2c | |
| ATE448230T1 (de) | Für die behandlung von obesitas geeignete tricyclische amidderivate | |
| ECSP11010782A (es) | Derivados de 4,5-dihidro-oxazol-2-ilo | |
| TW200626152A (en) | Pyridine derivatives and pharmaceutical compositions and uses thereof | |
| ATE486058T1 (de) | Prolinamidderivate als nk3-antagonisten | |
| BR112012003916A2 (pt) | derivados de pirrolidinas como antagonistas de receptores nk3 | |
| CR10036A (es) | Procedimientos para la preparación de derivados de ciclopropilamida | |
| CR10037A (es) | Procedimientos novedosos para la preparación de derivados de piperacinil y diazapanil benzamida | |
| ATE323094T1 (de) | Antidepressiv wirkende cycloalkylaminderivate von mit heterocyclen kondensierten benzodioxanen | |
| IL188115A0 (en) | 8-alkoxy-4-methyl-3,4-dihdro-quinazolin-2- | |
| BRPI0513468A (pt) | método de produção de 3-(4-piperidinil)-2,3,4,5-tetrahidro-1,3-benzodia-zepin-2 (1h)-ona | |
| EA015500B9 (ru) | Новые антагонисты мсн рецепторов | |
| ATE484500T1 (de) | Synthese von ccr5 rezeptor antagonisten |